Related Experiment Videos
Sentinel lymph node biopsy and breast cancer
1Surgical Center, Kanazawa University Hospital, Takara-machi 13-1, Kanazawa 920-8640, Japan.
The British Journal of Surgery
|February 20, 2002
Summary
Sentinel lymph node (SLN) biopsy is a feasible and accurate method for breast cancer staging. For T1 tumors, SLN biopsy can potentially replace routine axillary lymph node dissection (ALND), even with micrometastases.
Area of Science:
- Oncology
- Surgical Pathology
Background:
- Sentinel lymph node (SLN) biopsy is a critical technique in breast cancer staging.
- Accurate detection of micrometastases is essential for treatment decisions.
Purpose of the Study:
- To review the feasibility and accuracy of SLN biopsy in breast cancer.
- To propose a strategy for potentially eliminating routine axillary lymph node dissection (ALND).
Main Methods:
- Standardized methods for SLN identification using dye and gamma probe guidance.
- Histopathological analysis including step sectioning, H&E staining, and immunohistochemistry for micrometastasis detection.
Main Results:
- Combined dye and gamma probe guidance enhances SLN identification.
- SLN biopsy accuracy is comparable for T1 and T2 tumors.
- Patients with T1 tumors and SLN micrometastases showed no non-sentinel node involvement, suggesting ALND avoidance is possible.
Conclusions:
- Routine ALND can be avoided in T1 breast cancer patients with histologically negative SLNs.
- Prospective randomized trials are needed to confirm SLN biopsy as a replacement for routine ALND, especially for T2 tumors.